Latest news with #NurixTherapeutics
Yahoo
15-07-2025
- Business
- Yahoo
Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright
H.C. Wainwright lowered the firm's price target on Nurix Therapeutics (NRIX) to $34 from $36 and keeps a Buy rating on the shares. Nurix last week reported a Q2 net loss of (52c) per share, slightly narrower than the firm's previously estimated net loss of (62c) per share, the analyst tells investors in a research note. The firm is factoring in greater operating expenses moving forward. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on NRIX: Disclaimer & DisclosureReport an Issue Top 3 Trending Stocks, According to Analysts – 7/11/2025 Optimistic Buy Rating for Nurix Therapeutics Amid Regulatory and Strategic Catalysts Nurix Therapeutics price target lowered to $30 from $32 at Oppenheimer Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating Positive Outlook for Nurix Therapeutics: Strong Financials and Promising Clinical Progress Support Buy Rating
Yahoo
03-07-2025
- Business
- Yahoo
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Wall Street expects a year-over-year increase in earnings on higher revenues when Nurix Therapeutics, Inc. (NRIX) reports results for the quarter ended May 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This company is expected to post quarterly loss of $0.70 per share in its upcoming report, which represents a year-over-year change of +1.4%. Revenues are expected to be $19.81 million, up 63.9% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Nurix Therapeutics, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +4.74%. On the other hand, the stock currently carries a Zacks Rank of #2. So, this combination indicates that Nurix Therapeutics will most likely beat the consensus EPS estimate. While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Nurix Therapeutics would post a loss of$0.72 per share when it actually produced a loss of -$0.67, delivering a surprise of +6.94%. Over the last four quarters, the company has beaten consensus EPS estimates just once. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Nurix Therapeutics appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Another stock from the Zacks Medical - Biomedical and Genetics industry, Nurix Therapeutics, Inc. (NRIX), is soon expected to post loss of $0.7 per share for the quarter ended May 2025. This estimate indicates a year-over-year change of +1.4%. Revenues for the quarter are expected to be $19.81 million, up 63.9% from the year-ago quarter. Over the last 30 days, the consensus EPS estimate for Nurix Therapeutics has remained unchanged. Nevertheless, the company now has an Earnings ESP of +4.74%, reflecting a higher Most Accurate Estimate. This Earnings ESP, combined with its Zacks Rank #2 (Buy), suggests that Nurix Therapeutics will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed EPS estimates just once. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nurix Therapeutics, Inc. (NRIX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
17-06-2025
- Business
- Business Insider
Analysts' Top Healthcare Picks: Nurix Therapeutics (NRIX), Disc Medicine (IRON)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nurix Therapeutics (NRIX – Research Report), Disc Medicine (IRON – Research Report) and Silence Therapeutics (SLN – Research Report) with bullish sentiments. Confident Investing Starts Here: Nurix Therapeutics (NRIX) In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Nurix Therapeutics, with a price target of $25.00. The company's shares closed last Thursday at $11.96, close to its 52-week low of $11.90. According to Archila is a 5-star analyst with an average return of 9.3% and a 50.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, Monte Rosa Therapeutics, and Apellis Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nurix Therapeutics with a $29.43 average price target, a 137.9% upside from current levels. In a report issued on June 2, Needham also maintained a Buy rating on the stock with a $27.00 price target. Disc Medicine (IRON) In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Disc Medicine. The company's shares closed last Thursday at $52.71. According to Bancroft is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.9% and a 37.1% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Protagonist Therapeutics, and Whitehawk Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Disc Medicine with a $99.10 average price target, implying a 95.9% upside from current levels. In a report issued on June 10, Raymond James also initiated coverage with a Buy rating on the stock with a $89.00 price target. Silence Therapeutics (SLN) In a report released today, Myles Minter from William Blair reiterated a Buy rating on Silence Therapeutics. The company's shares closed last Thursday at $5.59, close to its 52-week low of $3.19. According to Minter is a 4-star analyst with an average return of 6.9% and a 47.1% success rate. Minter covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Neumora Therapeutics, Inc., and Entrada Therapeutics Inc.
Business Insider
17-06-2025
- Business
- Business Insider
RBC Capital Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)
RBC Capital analyst Brian Abrahams maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) yesterday and set a price target of $28.00. The company's shares closed yesterday at $11.96. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Abrahams covers the Healthcare sector, focusing on stocks such as Incyte, Biogen, and Gilead Sciences. According to TipRanks, Abrahams has an average return of -1.9% and a 43.49% success rate on recommended stocks. Currently, the analyst consensus on Nurix Therapeutics is a Strong Buy with an average price target of $29.43, representing a 146.07% upside. In a report released today, Barclays also maintained a Buy rating on the stock with a $31.00 price target. The company has a one-year high of $29.56 and a one-year low of $8.18. Currently, Nurix Therapeutics has an average volume of 995.3K.
Business Insider
17-06-2025
- Business
- Business Insider
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on June 10, 2025, the company granted inducement awards to seventeen new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted stock options to purchase an aggregate of 97,400 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 66,750 shares of Nurix common stock. One fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of the employee's date of hire and one forty-eighth of the total number of shares underlying the stock options will vest each month thereafter until the stock option is fully vested on the fourth anniversary of the employee's date of hire, subject to the employee's continued service with Nurix on each such vesting date. The stock options have a term of ten years and an exercise price of $12.79 per share, which is equal to the closing price of Nurix's common stock on the grant date as reported by the Nasdaq Global Market. One fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the RSU vesting start date, which is July 30, 2025, subject to the employee's continued service with Nurix on the vesting date. Thereafter, one sixteenth of the total number of shares subject to the RSUs shall vest quarterly, until the RSU award is fully vested on the fourth anniversary of the vesting start date, subject to the employee's continued service with Nurix on each such vesting date. About Nurix Therapeutics, Inc. Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix's partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix's dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine's next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit Elizabeth Wolffe, Ph.D. Wheelhouse Life Science Advisors lwolffe@ Media Aljanae Reynolds Wheelhouse Life Science Advisors areynolds@
